血清肿瘤M2型丙酮酸激酶诊断非小细胞肺癌的临床价值

摘要

Objective To evaluate the diagnosis value of serum tumor type M2 pyruvate kinase (Tu M2-PK) expression in patients with non-small-cell lung cancer (NSCLC) and its clinical value as tumor biomarker. Methods A total of 71 NSCLC patients and 48 cases of benign lung disease patients, who admitted to Department of Respiratory of Yan'an People's Hospital from January 2014 to September 2016, were respectively selected as the disease group and the control group. Serum Tu M2-PK was measured in the two groups by using enzyme linked immunosorbent assay (ELISA). According to Bayesian quantification method, the sensitivity and specificity of NSCLC and benign lung le-sions identified by Tu M2-PK and the area under the receiver operating characteristic curves (AUC-ROC) were evaluat-ed by ROC. Results Serum Tu M2-PK were 21.6 U/mL and 6.1 U/mL in the disease group and the control group, which demonstrated skewness distribution. The mean log (Tu M2-PK) in the disease group and the control group were (1.21 ± 0.71) and (0.72 ± 0.39), respectively, with significant statistical difference (P<0.05). The diagnosis sensitivity and specificity for Tu M2-PK as the biomarker were 78.1％ and 65.2％, respectively with AUC-ROC of 0.81 (95％CI:0.74-0.89). Conclusion Tu M2-PK in patients with NSCLC is significantly higher than that in non-tumor lung disease patients, which can be used as a serological marker for the differential diagnosis of NSCLC and benign lung lesions.%目的 探讨血清肿瘤M2型丙酮酸激酶(M2-PK)在非小细胞肺癌(NSCLC)患者及肺部良性病变中的表达水平及其作为血清学标志物的临床价值.方法 选取2014年1月至2016年9月延安市人民医院呼吸内科收治的71例NSCLC患者(病例组)和48例肺部良性病变患者(对照组)为研究对象.采用ELISA法分别检测两组患者的血清M2-PK浓度,根据贝叶斯定量采用ROC曲线评价M2-PK鉴别NSCLC与肺部良性病变的敏感性、特异性及ROC曲线下面积.结果 病例组和对照组患者血清M2-PK呈偏态分布,中位数分别为21.6 U/mL和6.1 U/mL,对数据进行10为底数的对数转换后病例组和对照组M2-PK分别为(1.21±0.71)和(0.72±0.39),病例组显著高于对照组,差异有统计学意义(P<0.05);以血清M2-PK为参考诊断NSCLC的敏感性为78.1％,特异性为65.2％,ROC曲线下面积AUC=0.81(95％CI:0.74～0.89).结论 非小细胞肺癌患者血清M2-PK明显升高,可作为鉴别NSCLC与肺部良性病变的血清学标志物.